Morgan Stanley
MRTX

Morgan Stanley’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Morgan Stanley’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-12,338,764
Closed -$725M – 8112
2023
Q4 		$725M Buy
12,338,764
+9,876,632
+401% +$555M 0.03% 526
2023
Q3 		$107M Sell
2,462,132
-382,340
-13% -$13.7M 0.01% 1013
2023
Q2 		$103M Buy
2,844,472
+793,019
+39% +$32.7M 0.01% 1076
2023
Q1 		$76.3M Buy
2,051,453
+361,742
+21% +$16.3M 0.01% 1222
2022
Q4 		$76.6M Buy
1,689,711
+702,556
+71% +$45.5M 0.01% 1201
2022
Q3 		$68.9M Buy
987,155
+81,721
+9% +$6.05M 0.01% 1108
2022
Q2 		$60.8M Buy
905,434
+780,024
+622% +$49.6M 0.01% 1240
2022
Q1 		$10.3M Buy
125,410
+98,718
+370% +$10.1M ﹤0.01% 2879
2021
Q4 		$3.92M Sell
26,692
-6,476
-20% -$1.01M ﹤0.01% 3972
2021
Q3 		$5.87M Sell
33,168
-43,459
-57% -$6.99M ﹤0.01% 3504
2021
Q2 		$12.4M Buy
76,627
+23,009
+43% +$3.69M ﹤0.01% 2743
2021
Q1 		$9.19M Sell
53,618
-166,436
-76% -$33M ﹤0.01% 2746
2020
Q4 		$48.3M Buy
220,054
+189,578
+622% +$41M 0.01% 1127
2020
Q3 		$5.06M Buy
30,476
+3,675
+14% +$503K ﹤0.01% 2703
2020
Q2 		$3.06M Sell
26,801
-2,015
-7% -$195K ﹤0.01% 3173
2020
Q1 		$2.22M Sell
28,816
-114,767
-80% -$10.3M ﹤0.01% 3275
2019
Q4 		$18.5M Buy
143,583
+103,055
+254% +$9.94M ﹤0.01% 1730
2019
Q3 		$3.16M Buy
40,528
+23,218
+134% +$2.18M ﹤0.01% 3365
2019
Q2 		$1.78M Buy
17,310
+4,266
+33% +$332K ﹤0.01% 3867
2019
Q1 		$956K Sell
13,044
-36,496
-74% -$2.48M ﹤0.01% 4139
2018
Q4 		$2.1M Sell
49,540
-3,835
-7% -$153K ﹤0.01% 3725
2018
Q3 		$2.51M Buy
53,375
+8,888
+20% +$495K ﹤0.01% 3820
2018
Q2 		$2.19M Buy
44,487
+29,690
+201% +$1.12M ﹤0.01% 3988
2018
Q1 		$454K Sell
14,797
-1,060
-7% -$29.4K ﹤0.01% 5062
2017
Q4 		$290K Sell
15,857
-150,235
-90% -$2.33M ﹤0.01% 5265
2017
Q3 		$1.94M Buy
166,092
+134,362
+423% +$777K ﹤0.01% 3916
2017
Q2 		$116K Sell
31,730
-21,270
-40% -$81.5K ﹤0.01% 5581
2017
Q1 		$276K Sell
53,000
-16,101
-23% -$88.2K ﹤0.01% 5160
2016
Q4 		$329K Buy
69,101
+31,701
+85% +$172K ﹤0.01% 5145
2016
Q3 		$247K Sell
37,400
-39,331
-51% -$209K ﹤0.01% 4920
2016
Q2 		$419K Buy
76,731
+28,528
+59% +$455K ﹤0.01% 4529
2016
Q1 		$1.03M Sell
48,203
-93,257
-66% -$2.09M ﹤0.01% 3915
2015
Q4 		$4.47M Buy
141,460
+10,873
+8% +$384K ﹤0.01% 2771
2015
Q3 		$4.5M Buy
130,587
+77,617
+147% +$2.35M ﹤0.01% 2754
2015
Q2 		$1.67M Buy
52,970
+36,159
+215% +$1.07M ﹤0.01% 3783
2015
Q1 		$493K Sell
16,811
-17,925
-52% -$420K ﹤0.01% 4660
2014
Q4 		$643K Buy
34,736
+7,730
+29% +$130K ﹤0.01% 4493
2014
Q3 		$474K Buy
27,006
+6,061
+29% +$113K ﹤0.01% 4607
2014
Q2 		$419K Sell
20,945
-34,370
-62% -$664K ﹤0.01% 4710
2014
Q1 		$1.05M Buy
55,315
+45,813
+482% +$952K ﹤0.01% 3953
2013
Q4 		$158K Buy
+9,502
New +$162K ﹤0.01% 5139

Other funds holding MRTX

S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Morgan Stanley's MRTX Position: Q1 2024 in Review

Morgan Stanley sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 12,338,764 shares — an estimated $725M sold.

Morgan Stanley first reported a position in MRTX in Q4 2013 and held it in 41 quarters. The position peaked at $725M in Q4 2023. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

  • Morgan Stanley reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Morgan Stanley sold 12,338,764 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $725M.
  • Morgan Stanley first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2013 and held it in 41 quarters.
  • Morgan Stanley's Mirati Therapeutics, Inc. Common Stock position peaked at $725M in Q4 2023.
  • 2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Morgan Stanley's 13F filing for Q1 2024, filed 15 May 2024.